Lifitegrast

Overview

Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC 50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > SARS-CoV-2 Infection | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Integrin

Product Information

• Catalog No.: HY-19344
• CAS No.: 1025967-78-5
• Molecular Formula: C29H24Cl2N2O7S
• Molecular Weight: 615.48
• Purity: 99.29%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.5 mg/mL (4.06 mM); Clear solution
• Availability: In-stock

Source

Original product source